These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 20153398)

  • 41. Progress in Parkinson's disease.
    Schapira AH
    Eur J Neurol; 2008 Jan; 15(1):1. PubMed ID: 18171385
    [No Abstract]   [Full Text] [Related]  

  • 42. [Arguments in favor of early treatment of Parkinson's disease with dopaminergic agonists].
    Rascol O
    Rev Neurol (Paris); 1999 Jan; 155(1):35-42. PubMed ID: 10093846
    [No Abstract]   [Full Text] [Related]  

  • 43. Clozapine: new preparation. A last resort for parkinsonian patients with psychosis.
    Prescrire Int; 2002 Feb; 11(57):1-6. PubMed ID: 11985366
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [L-dopa effectiveness decreases over time. What helps Parkinson patients stay mobile?].
    Wedekind S
    MMW Fortschr Med; 2005 Jun; 147(22):10. PubMed ID: 15977622
    [No Abstract]   [Full Text] [Related]  

  • 45. [Treatment of parkinsonism and legal capacity].
    Wallesch CW
    Fortschr Neurol Psychiatr; 2011 Aug; 79(8):441. PubMed ID: 21809256
    [No Abstract]   [Full Text] [Related]  

  • 46. Long-standing paraphilia induced by dopamine agonists in Parkinson's disease.
    Pineau F; Schüpbach M; Corvol JC; Flamand-Rouvière C; Vidailhet M; Roze E
    Mov Disord; 2010 May; 25(7):963-5. PubMed ID: 20461818
    [No Abstract]   [Full Text] [Related]  

  • 47. Pharmacotherapy for Parkinson's disease: current options, promising future therapies.
    Moser SS; Besler-Panos W
    JAAPA; 2006 Aug; 19(8):38-44. PubMed ID: 16918085
    [No Abstract]   [Full Text] [Related]  

  • 48. L-dopa treatment duration versus Parkinson's disease progression: the dorsal-ventral divide.
    Belujon P; Grace AA
    Mov Disord; 2013 Feb; 28(2):120-1. PubMed ID: 23401218
    [No Abstract]   [Full Text] [Related]  

  • 49. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease.
    Cools R
    Neurosci Biobehav Rev; 2006; 30(1):1-23. PubMed ID: 15935475
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Parkinson syndrome: iatrogenic causes, iatrogenic treatment results].
    Burgunder JM
    Schweiz Med Wochenschr; 1996 Mar; 126(13):522-7. PubMed ID: 8658091
    [TBL] [Abstract][Full Text] [Related]  

  • 51. When a Parkinson's disease patient starts to hallucinate.
    Poewe W
    Pract Neurol; 2008 Aug; 8(4):238-41. PubMed ID: 18644910
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Hallucinations in Parkinson's disease].
    Moser A; Hagenah J; Kömpf D
    Nervenarzt; 2003 Apr; 74(4):376-85, quiz 385-6. PubMed ID: 12707709
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson's disease.
    Merims D; Giladi N
    Parkinsonism Relat Disord; 2008; 14(4):273-80. PubMed ID: 17988927
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Stocchi F
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S9-S15. PubMed ID: 19131046
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clozapine prevents recurrence of psychosis in Parkinson's disease.
    Factor SA; Brown D
    Mov Disord; 1992; 7(2):125-31. PubMed ID: 1350059
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Features associated with the development of hallucinations in Parkinson's disease.
    Benbir G; Ozekmekçi S; Cinar M; Beskardes F; Apaydin H; Erginöz E
    Acta Neurol Scand; 2006 Oct; 114(4):239-43. PubMed ID: 16942542
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment of Parkinson's disease--where do we go from here?
    Suchowersky O
    Nat Clin Pract Neurol; 2006 Sep; 2(9):461. PubMed ID: 16932605
    [No Abstract]   [Full Text] [Related]  

  • 58. Drug treatment of Parkinson's disease.
    Callaghan N
    Ir Med J; 1983 Aug; 76(8):364-6. PubMed ID: 6618850
    [No Abstract]   [Full Text] [Related]  

  • 59. Parkinson's disease.
    Wolters EC; Calne DB
    CMAJ; 1989 Mar; 140(5):507-14. PubMed ID: 2563667
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Neuroleptic malignant syndrome in parkinsonian patients: risk factors.
    Kuno S; Mizuta E; Yamasaki S
    Eur Neurol; 1997; 38 Suppl 2():56-9. PubMed ID: 9387804
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.